文献速递肝肾功能剂量调整特殊人群用药

曲妥珠单抗德鲁替康在HER2阳性乳腺癌及其他实体瘤患者中的群体药代动力学

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
PubMed 文献 · Clin Pharmacol Ther · 2020-12-06

曲妥珠单抗德鲁替康(DS-8201)是一种靶向HER2的抗体药物偶联物,药物抗体比约8。本研究基于5项临床研究、639例患者的汇总数据,采用非线性混合效应模型分析其群体药代动力学。结果显示,除体重增加(第95百分位,86 kg)和白蛋白降低(第5百分位,31 g/L)外,其他协变量对稳态暴露的影响均小于20%,且按国家、种族、肾功能和肝功能分层未见临床有意义的暴露差异,提示无需根据所测协变量或特定患者人群调整剂量。

要点

  • 曲妥珠单抗德鲁替康的群体PK可用二室线性消除模型描述。
  • 释放药物PK用一室模型描述,释放速率常数随时间变化。
  • 除体重增加和白蛋白降低外,协变量对稳态暴露影响小于20%。

核心结论

  • 曲妥珠单抗德鲁替康及其释放药物的稳态暴露在按国家、种族、肾功能和肝功能分层的患者中无临床有意义差异,无需根据所测协变量或特定患者人群调整剂量。

研究设计与样本

  • 基于5项临床研究、639例HER2阳性乳腺癌或其他实体瘤患者的汇总数据,采用非线性混合效应模型进行群体药代动力学分析。
  • 曲妥珠单抗德鲁替康剂量范围为每3周0.8至8.0 mg/kg。
  • 采用序贯两步法分析曲妥珠单抗德鲁替康和释放药物的血清浓度。

主要发现

  • 二室线性消除模型最佳描述完整曲妥珠单抗德鲁替康的PK特征。
  • 一室模型伴时变释放速率常数和线性消除描述释放药物的PK特征。
  • 有统计学意义的协变量(国家、肿瘤大小、性别、制剂、年龄、体重、白蛋白、总胆红素和天冬氨酸氨基转移酶)导致稳态AUC变化小于20%,但体重增加(第95百分位,86 kg)和白蛋白降低(第5百分位,31 g/L)除外。

关键数值与推荐

  • 体重增加至第95百分位(86 kg)和白蛋白降低至第5百分位(31 g/L)时,稳态AUC变化超过20%。
  • 按国家、种族、肾功能和肝功能分层,稳态暴露无临床有意义差异。

临床怎么用

  • 基于现有分析,无需根据所测协变量或特定患者人群(如肾功能或肝功能异常)调整曲妥珠单抗德鲁替康剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of ≈ 8. We have characterized the population pharmacokinetics (PK) of trastuzumab deruxtecan and released drug (topoisomerase I inhibitor) in patients with HER2-positive breast cancer or other solid tumor malignancies. This analysis includes pooled data from five clinical studies with 639 patients. Trastuzumab deruxtecan doses ranged from 0.8 to 8.0 mg/kg every 3 weeks. Serum concentrations of trastuzumab deruxtecan and released drug were analyzed using a sequential two-step approach, with the nonlinear mixed-effects modeling methods. Covariate assessment was based upon stepwise forward-addition and backward-elimination process, followed by both univariate and multivariate analysis quantifying their impact on steady-state exposure of trastuzumab deruxtecan and released drug. A two-compartment model with linear elimination best described PK profiles of intact trastuzumab deruxtecan, while a one-compartment model with time-varying release-rate constant and linear elimination described released-drug PK profiles. Statistically significant covariates (country, tumor size, sex, formulation, age, body weight, albumin, total bilirubin, and aspartate aminotransferase) resulted in < 20% change in steady-state area under the concentration-time curve of trastuzumab deruxtecan and released drug, except for increased body weight (95th percentile, 86 kg) and decreased albumin (5th percentile, 31 g/L). Analysis of patients stratified by country, race, renal function, and hepatic function found no clinically meaningful differences in steady-state exposure of intact trastuzumab deruxtecan or released drug. Overall, results suggest that no dose adjustment based on tested covariates or in specific patient populations is warranted.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yin O, Xiong Y, Endo S, et al. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors. Clin Pharmacol Ther. 2020. PMID: 33118153. doi:10.1002/cpt.2096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。